There are few available adjuvant/neoadjuvant medicines for treatment of high-risk resectable colorectal cancer. Lack of pipeline agents in this setting presents a good opportunity for development of effective treatments that can improve cure rates for resected patients.

Market Analysis and Insights: Global Colorectal Cancer Drugs Market
In 2020, the global Colorectal Cancer Drugs market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% between 2021 and 2027
Global Colorectal Cancer Drugs Scope and Market Size
The global Colorectal Cancer Drugs market is segmented by region (country), company, by Type, and by Application. Players, stakeholders, and other participants in the global Colorectal Cancer Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), byType, and by Application for the period 2016-2027.

Segment
Vascular Endothelial Growth Factor (VEGF) Inhibitors
Epidermal Growth Factor Receptor (EGFR) Inhibitors
Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
BRAF or MEK Inhibitors
Tyrosine Kinase (TKI) Inhibitors
Immunomodulators

Segment
Radiotherapy
Chemotherapy

By Company
AB Science
Amgen
Array BioPharma
Bayer
Boehringer Ingelheim
Bristol-Myers Squibb
Elli Lilly
Roch
Hutchison MediPharma
Merck & Co., Inc.
Mologen
Regeneron
Sanofi
Sumitomo Dainippon
Taiho Pharmaceutical
Vaccinogen

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Colombia
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE